Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine for Marijuana Addiction and Depression
NCT00131456Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2004
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cannabis use disorder (CUD) and major depressive disorder (MDD) comparing Venlafaxine with Placebo (2 arms). Primary endpoint: Two Consecutive Weeks of Marijuana Abstinence at 12 weeks. Started Mar 2004; status: completed.
02
Drugs
venlafaxine
03
Conditions
cannabis use disorder (CUD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00131456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131456.